Interferon-␥ (IFN-␥) plays an important role in the immunomodulation and growth inhibition of many tumor cells, but its clinical application is limited by its systemic toxicity. Ad/hIFN-␥, a nonreplicating adenoviral vector encoding human IFN-␥, has been reported to inhibit tumor growth in vitro and in a xenograft model. In this study, the long-term toxicity of Ad/hIFN-␥ was assessed in cynomolgus macaques (Macaca fascicularis). Thirty animals were enrolled into 5 groups, and administered intramuscularly, respectively, Ad/hIFN-␥ (3.3 ϫ 10 10 , 3.3 ϫ 10 11 , or 3.3 ϫ 10 12 VP/kg), Ad/LacZ (vector control, 3.3 ϫ 10 11 VP/kg), or excipient 3 times per week for 8 weeks, followed by a 4-week recovery period. At 12 weeks all experimental animals appeared generally healthy, and there were no statistically significant differences in body weight, urinalysis, hemogram, blood biochemistry, and electrocardiogram results between the treatment and control groups. No significant toxic effects were noted on macroscopic and microscopic examinations of organs and tissues. Preliminary investigation of the immunotoxicity of Ad/IFN-␥ indicated that anti-adenoviral and anti-hIFN-␥ antibodies were generated. These data demonstrate that long-term, high-dose intramuscular administration of Ad/IFN-␥ was not notably toxic and might be safe for clinical therapeutic use.
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Introduction
I
NTERFERON (IFN)-␥ WAS ORIGINALLY BELIEVED to be produced as a defensive response in virally infected or parasite-invaded cells (De Maeyer and De Maeyer-Guignard, 1992; Nishikawa et al., 2001; Mansfield and Paulnock, 2005; Urban et al., 2005; Mujtaba et al., 2006) . Extensive research has demonstrated that IFN-␥ plays a critical role in a multitude of immunological processes, and is vital to promote tumor surveillance in immunocompetent hosts. IFN-␥ upregulates the expression of major histocompatibility complex (MHC) class I and class II molecules in a variety of cells (Weber and Rosenberg, 1988; Beniers et al., 1991) , as well as tumor-associated antigens in vivo and in vitro. This latter effect increases the susceptibility of tumor antigens processed by antigenpresenting cells (APCs) then submitted to CD8 ϩ cytotoxic T cells for lysis of tumor cells (Carrel et al., 1985; Guadagni et al., 1994) . IFN-␥ can exert direct antiproliferative and antimetabolic effects on a variety of tumor cells and it synergizes with tumor necrosis factor (TNF)-␣ and -␤ in inhibiting the proliferation of various cell types (Farrar and Schreiber, 1993; Ikeda et al., 2002; Khan et al., 2006) . Other evidence indicates that some of the antitumor effects of IFN-␥ may be mediated through a mechanism involving inhibition of angiogenesis within the tumor (Ribatti et al., 2006) . In addition, the innate immune responses against tumors are activated. IFN-␥ activates macrophages to nonspecifically kill a variety of tumor targets in vitro and in vivo (Schreiber et al., 1986) .
In vitro evidence of the potent antitumor activity of IFN-␥ suggests that the cytokine may be a promising treatment to prevent tumor growth and slow cancer progression. However, systemic administration of IFN-␥ has been shown to be generally unsuccessful and strong side effects limit its clinical use (Creagan et al., 1988; Osanto et al., 1989) . When given in phase I clinical trials, recombinant IFN-␥ induced serious side effects, including transient fever, nausea, headaches, and flulike symptoms (Halme et al., 1994; Reddy et al., 1997) . One approach to avoid these problems would be to use gene therapy. IFN-␥ can be directly delivered to the tumor site and maintain its anticancer activity while avoiding much of the toxic side effects. An IFN-␥ retroviral vector has been administered intratumorally to patients with metastatic melanoma in a phase I trial (Nemunaitis et al., 1999) . However, the use of a retroviral vector meant that the possibility of its integration into host DNA could not be ruled out. Recombinant adenoviruses are the most commonly used vectors in genetic cancer vaccines (Butterfield et al., 1998; Kaplan et al., 1999; Mascola, 2006) . To date, all adenoviral vectors used clinically are based on serotype 5 (Chirmule et al., 1999; Jooss and Chirmule, 2003) . Ad/hIFN-␥ is a replication-incompetent recombinant adenovirus in which human IFN-␥ was inserted into an Ad5-based vector. Preclinical work in our laboratory established that sustained expression of human IFN-␥ in several different cell lines (including prostate carcinoma DU-145, PC-3, and human leukemia cell line K562) could inhibit tumor cell proliferation and hepatic fibrosis in vitro and in vivo (L. Li et al., 2006; Zhao et al., 2007) .
In anticipation of possible future clinical trials using Ad/hIFN-␥ as an anticancer medicine, 30 cynomolgus macaques (Macaca fascicularis) were used to determine the potential systemic toxicity of Ad/hIFN-␥ after a 2-month administration. Intramuscular delivery was chosen because Ad/hIFN-␥ will be injected into tumors in subsequent clinical trials. The objective of the study was to determine the safety of localized injections of Ad/hIFN-␥.
Materials and Methods
Cell lines and recombinant adenoviral vectors
HEK-293 cells (CRL-1573; American Type Culture Collection, Manassas, VA) and Vero cells (CCL-81; American Type Culture Collection) were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (100 g/ml) (Invitrogen, Carlsbad, CA). Recombinant Ad5 (E1/E3 -)-based vectors encoding ␤-galactosidase (Ad/LacZ) and human interferon-␥ (Ad/IFN-␥) were constructed as previously reported (Huang and Flint, 1998; Liu et al., 2005; L. Li et al., 2006; X. Li et al., 2006) . All viruses were amplified in HEK-293 cells, purified by cesium chloride gradient centrifugation, and titered with an Adeno-X rapid titer kit (Clontech, Palo Alto, CA). Viruses were prepared according to standard operating procedures and stored in preservative buffer (PB) (0.01 M Tris-HCl, 0.1 M NaCl, 0.001 M MgCl 2 , 10% glycerol; pH 8.5) at Ϫ80°C. They were checked and verified to be free of bacteria, fungus, mycoplasma, endotoxin, and replicationcompetent adenovirus.
Animals and procedures
All animal studies were performed at Kangda Experimental Animal Center (Guangzhou, China) in accordance with the institutional guidelines of Sun Yat-sen University (Guangzhou, China). Thirty cynomolgus macaques (Macaca fascicularis) (n ϭ 15 per sex; age, 2.5-3 years; weight, 2-3 kg) were enrolled in the study. Animals were individually caged.
Animals were divided into five groups (n ϭ 6 per group, three animals per sex), three of which received Ad/hIFN-␥ at the following doses: 3.3 ϫ 10 10 VP/kg (low-dose group), 3.3 ϫ 10 11 VP/kg (mid-dose group), or 3.3 ϫ 10 12 VP/kg (high-dose group). The other two groups were controls: Ad/LacZ (at 3.3 ϫ 10 11 VP/kg) and excipient (1 ml of PB per dose). Cohorts of animals were injected intramuscularly (quadriceps femoris), three times per week (Tuesday, Thursday, and Saturday), for eight successive weeks. The selected doses were based on the use of weight conversion between monkey and human and were equivalent to 2, 20, and 200 times of clinical doses, respectively. The doses were determined according to General Principles on Nonclinical Safety Technical Evaluation of Biological Products Designed for Disease Treatment, established by State Food and Drug Administration of China.
On week 8 (1 day after the last injection), three animals from each group (two males and one female) were killed. Other animals were kept for another 4 weeks (recovery period). Tissue collection and processing were performed as described in detail elsewhere (Morral et al., 2002) . Blood was collected from each animal at several time points. The time schedule is shown in Table 1 .
General observations
Each animal was monitored for general condition on a daily basis, beginning the day before the first treatment. The general condition of the animals included examination of appearance, activity, gland secretion, breath, color of urine and feces, and food consumption. Body weight and body temperature were monitored as described in Table 1 .
Electrocardiogram examinations
Electrocardiogram (ECG) examination was performed with a Cardiofax ECG-9020 electrocardiograph (Nihon Kohden, Tokyo, Japan) at weeks 0, 4, 8, and 12, respectively. Heart rate; P-R, Q-T, and QRS intervals; the presence of ST-T wave change; and ectopic rhythm were recorded at all time points.
Hematology analysis
Hematology analysis, including red blood cell count (RBC), hemoglobin concentration (HGB), hematocrit value (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), reticulocyte count (RET), total leukocyte count (WBC), leukocyte differential count (WBCDC) (neutrophil, lymphocyte, monocyte, eosinophil, and basophil), platelet count (PLT), mean platelet volume (MPV), and prothrombin time (PT) were evaluated at various time points.
Blood biochemistry analysis and urinalysis
Blood biochemistry analysis included aspartate aminotransferase (AST), alanine aminotransferase (ALT), ␥-glutamyltransferase (GGT), alkaline phosphatase (ALP), blood urea nitrogen (BUN), total protein (TP), albumin (ALB), glucose (GLU), total bilirubin (TBIL), creatinine (Crea), total LI ET AL. 2 cholesterol (TCHO), triglyceride (TG), lactic acid dehydrogenase (LDH), and Na ϩ , K ϩ , and Cl -. Concentrations of Na ϩ , K ϩ , and Cl -were tested with an EasyLyte Plus Na/K/Cl analyzer (Medica, Bedford, MA), whereas other parameters were examined with a Hitachi 7020 automatic biochemistry analyzer (Hitachi, Tokyo, Japan).
Urine samples were collected continuously for 12 hr. Urine tests included glucose (Glu), bilirubin (Bil), ketobodies (Ket), protein (Pro), nitrite (Nit), urine occult blood (Bld), white blood cells (Leu), specific gravity (SG), pH value, and urobilinogen (UBG). Fresh urine was analyzed with a 10-item test paper according to the instructions of the manufacturer (Siemens Medical Solutions Diagnostics, Malvern, PA).
Systemic autopsy and organ coefficients
Comprehensive necropsy was performed at the time of sacrifice. Subcutaneous bleeding points, infection, and lymph node hyperplasia were investigated. Selected organs (heart, thymus, liver, spleen, lung, kidney, brain, ovary, testicle, uterus, epididymis, adrenal glands, and prostate) were weighed before fixation, and the organ coefficient was calculated according to the Operating Autopsy Instructions for Experimental Animals (http://www.research.psu.edu/arp/ experiment.shtml) as follows: For thyroid, adrenal glands, pituitary gland, and ovaries, organ coefficient ϭ [organ weight (mg)/body weight (g)] ϫ 100 g body weight; for other organs, organ coefficient ϭ [organ weight (g)/body weight (g)] ϫ 100 g body weight.
Histopathologic analysis
Tissues adjacent to the injection site, and a comprehensive panel of organs and tissues, including heart, liver, spleen, lung, kidney, stomach, duodenum, ileum, colon, lymph nodes (mesentery and inguinal), bladder, testis, epididymis, uterus, ovary, thymus, adrenal glands, pancreas, thyroid gland, parathyroid gland, esophagus, trachea, prostate, brain (cerebrum, cerebellum, and brainstem), pituitary, optic nerve, spinal cord (neck, chest, and waist), sternum (bone and bone marrow) were collected, fixed, and examined histopathologically.
Quantitative polymerase chain reaction for virus genomes and detection of IFN-␥
Isolation of genomic DNA from 50 l of serum (collected at time 0, and 4, 12, 24, and 48 hr after the first injection) was performed with a serum DNA isolation kit (Invitrogen). Primers and probe were designed to be specific for the recombinant virus, but not found in wild-type adenoviral sequences. The following primers and probe were used: forward primer, adv-IFN-65F (5Ј-GGA GGG CCA CCA TGA AAT ATA-3Ј; reverse primer, adv-IFN-139R (5Ј-AAC AGC CAA GAG AAC CCA AA-3Ј); and probe (5Ј-FAM-ATC TTG GCT TTT CAG CTC TGC ATC G-TAMRA-3Ј) (SBS Genetech, Beijing, China). Samples were analyzed with TaqMan universal PCR master mix (Applied Biosystems, Foster City, CA) on an ABI PRISM 7900HT sequence detection system (Applied Biosystems). The serial dilution of Ad/hIFN-␥ was used to generate the standard curve. Analysis of the data was performed with the ABI PRISM 7000 SDS software (Applied Biosystems).
Serum taken at time 0, and at 4, 12, 24, and 48 hr (after the first injection) were measured with an enzyme-linked immunosorbent assay (ELISA) kit for human IFN-␥ (Invitrogen BioSource Division, Camarillo, CA).
Detection of anti-adenovirus antibodies and neutralizing antibodies
Anti-adenovirus antibodies were titered with an ELISA kit (Jingmei Biotech, San Diego, CA). Briefly, serum samples diluted 1:50 were added to wells and incubated, rinsed, and incubated with horseradish peroxidase (HRP)-conjugated goat anti-rhesus IgG (diluted 1:4000; SouthernBiotech, Birmingham, AL) or anti-monkey IgM (diluted 1:2000; Alpha Diagnostic International, San Antonio, TX), and then rinsed and incubated with the substrate solution. After the color developed, the reaction was terminated, and the optical density at 450 nm (OD 450 nm ) was determined (Multiskan EX with Genesis software; Thermo Fisher Scientific, Waltham, MA). Samples were analyzed in triplicate. Neutralizing antibodies to adenovirus type 5 were assayed as described previously (Slos et al., 2001; L. Li et al., 2006) . Sera were heat inactivated at 56°C for 30 min, and serial 2-fold dilutions of sera were prepared. The fluorescence at 365 nm (excitation) and 455 nm (emission) was recorded with a multifunctional plate reader (GENios FL; Tecan Group, Männedorf, Switzerland). The titer of neutralizing antibodies was expressed as the inverse of the dilution required to produce 50% reduction in LacZ activity.
For further analysis of adenovirus-neutralizing antibody, monkey sera from the various groups at week 4 were mixed and heat inactivated. Serial dilutions of Ad/GFP (10 6 , 10 5 , 10 4 , 10 3 , and 10 2 infectious units [IFU] ) in 100 l of FBS-free DMEM were mixed with 10 l of heat-inactivated sera, and incubated at room temperature for 1 hr. Vero cells were then infected. After 30 hr of incubation, cells were observed with a fluorescence microscope.
Detection of anti-human IFN-␥ antibodies
A 96-well microtiter plate was coated with recombinant human IFN-␥ (Invitrogen) at 0.1 g/well. Monkey serum were added at 1:4 dilution and incubated for 30 min at 37°C, the plate was washed four times and incubated with HRP-conjugated goat anti-rhesus IgG (SouthernBiotech) for 30 min at 37°C, the substrate was added, and finally the plate was read at OD 450 nm (Multiskan EX with Genesis software).
Statistical analysis
Results are expressed as means Ϯ standard deviation (SD) of each experimental group. Data analysis was performed by analysis of variance. p Ͻ 0.05 was considered significant.
Results
General findings and ECG
Over the entire course of the study, there were no significant differences observed in monkeys of each group: appearance, activity, gland secretion, breath, feces, and food consumption. Monkey 23 (male in the mid-dose group) died on day 29 of an overdose of anesthesia and thus did not survive to the end of the study. Overall, the monkeys had a generally healthy appearance. No significant weight loss was observed in any of the treatment groups when compared with the group that received excipient buffer alone (Fig. 1) . Compared with that before injection, no obvious change in body temperature was found 4 hr after injection, except that body temperature increased slightly in the three Ad/hIFN-␥-treated groups after the last (24th) injection (Table 2) .
There were no statistically significant differences in any parameter of the ECG examination between the groups at any time (p Ͼ 0.05) (data not shown), demonstrating that there were no cardiovascular effects induced by intramuscular injection of Ad/IFN-␥ into monkeys.
Hematology
As shown in Table 3 
FIG. 1.
Effects of Ad/hIFN-␥ on body weight. For animals in mid-dose group: n ϭ 6 (weeks 0-4); n ϭ 5 (weeks 5-8); n ϭ 2 (weeks 9-12). For animals in other groups: n ϭ 6 (weeks 0-8); n ϭ 3 (weeks 9-12). 3 (2) 
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(continued)
Serum and urine biochemistry
As shown in Table 4 , serum biochemical parameters, including AST, ALT, GGT, ALP, BUN, CR, TP, ALB, GLU, TBIL, Crea, TCHO, TG, LDH, Na ϩ , K ϩ , and Cl -, were all within normal range throughout the entire experimental schedule. No significant abnormalities about urine biochemistry were noted throughout the treatment schedule. (The data for urinalysis of animals tested are summarized in Supplementary Table 1 at www.liebertonline.com/hum.)
Systemic autopsy, organ coefficient, and histopathology examination
Gross examinations showed that there were no obvious abnormalities in organ anatomical position, appearance, size, color, firmness, surface, and sections of main organs in any of the experimental monkeys. Autopsied animals in each group had smooth hair, with no abnormal secretions in the eyes, nose, mouth, ears, genitals, or anus. The animals' lung surface was smooth and glossy, and lung position, texture, appearance, and color were normal, with no abnormal bleeding points or secretions. The position and color of the heart were normal and no abnormal secretions were observed either in the pericardium or in the thoracic cavities. There were no significant differences between control and treated groups in terms of liver surface color, position, or texture. The color and position of gall bladder, spleen, and pancreas were normal. The kidney surface was smooth and glossy, and color and position were normal. The stomach and intestines were empty, suggesting that food had been digested. There were no bleeding points on the surface of the duodenum, ileum, colon and rectum, and omenta. The appearance and position of the adrenal glands were normal. The ovaries were fully developed. The prostate was normal and the testis surface was white and clean, with no bleeding points. There was no food in the stomach, and there were no bleeding points or inflammatory signs on the gastric surface. The bladder was empty, with no signs of surface abnormality. Animals' skulls were opened with a saw. There was no ab-normal hydrops in encephaloceles. No bleeding or inflammatory exudation or thickening was observed in the subarachnoid cavity or cerebral pia mater blood vessels. The structure of parenchymatous tissues was clear.
There were no significant differences in major organ coefficients between the Ad/hIFN-␥-treated and control groups (p Ͼ 0.05), nor were abnormalities noted at the end of the recovery period (week 12 [W 12 ]) (see Supplementary  Table 2 at www.liebertonline.com/hum).
Histopathology was assessed in a number of tissues, including heart, kidney, liver, lung, and spleen. No abnormal morphological changes were noted in animals' heart, lungs, kidney, stomach, pancreas, adrenal glands, thymus, thyroid, parathyroid glands, brain (cerebrum, cerebellum, and brainstem), trachea, pituitary gland, spinal cord, bladder, esophagus, duodenum, jejunum, ileum, colon, lymph nodes (mesentery and inguinal), testes, epididymis, prostate, uterus, ovaries, sternum, and marrow. Slight hepatocyte edema was observed in one of six Ad/LacZ animals and one of six highdose animals but was not observed in other group animals. Inflammatory cell infiltration and fibroplasias were not observed at the liver in any group of animals. Slight splenic corpuscle hyperplasia was observed in some animals of each group: two excipient animals, two Ad/LacZ animals, three low-dose animals, three mid-dose animals, and four high-dose animals. These histopathological data suggested that successive intramuscular administrations of Ad/hIFN-␥ did not result in any notable toxic effect (Fig. 2) , as measured by pathological analysis.
Bone marrow
Previously, systemic administration of a high dose of adenoviral vector in nonhuman primates was shown to inhibit the growth of bone marrow progenitor cells (Schnell et al., 2001; Varnavski et al., 2002 Varnavski et al., , 2005 . Thus, we were interested in determining whether localized administration of Ad/hIFN-␥ would have a direct pathological effect on bone marrow. We evaluated bone marrow histopathology from paraffin-embedded sections from animals with or without Ad/hIFN-␥ treatment. Pathological signs, including macrophage infiltration and serious degeneration, were not apparent in any of the animals. These results indicate that intramuscular administration of Ad/hIFN-␥ does not result in bone marrow pathology.
Leakage of adenovirus into serum and hIFN-␥ in serum
We assessed recombinant adenoviral DNA in monkey serum at various time points, including 4, 12, 24, and 48 hr The number of copies of recombinant adenoviral DNA in serum samples of the low-dose group was not significantly different from those of the mid-dose group at any point in the study. In contrast, the high-dose group had a much higher number of copies (Fig. 3A) . We calculated the adenoviral copy number in the whole serum of monkeys on the basis of normal levels for the species, which is 150 ml in total (5% of body weight). Compared with the initial injection dose for each group, the percentage of recombinant adenovirus in serum was about 5, 2, and 1% for the low-, mid-, and high-dose groups, respectively. For the three Ad/hIFN-␥ treatment groups, human IFN-␥ levels in serum increased 12 hr after the first administration and reached peak levels at 24 hr (Fig. 3B) . The profile of IFN-␥ protein in serum was similar to the profile of recombinant adenoviral DNA in serum.
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Isotype characterization of anti-adenovirus antibodies
Serum samples were characterized by ELISA to determine the predominant isotype of adenovirus antibody present. For the three dose groups, Ad/hIFN-␥ treatment increased immunoglobulin G (IgG) levels in a dose-dependant way. IgG levels were elevated at week 2 and reached peak levels at week 4; then, at week 12 they decreased but remained higher than before treatment. IgM increased to a peak level at week 2 and returned to normal by week 4 (Fig. 4A and B) .
Adenovirus-specific neutralizing antibodies and neutralization of adenovirus infection
To ensure that complement mediated effects played no part in inhibition of virus infection, serum samples were subject to heat inactivation at 56°C for 30 min. Neutralizing antibodies in the three groups receiving Ad/hIFN-␥ increased to the levels (titer, 2 10 to 2 11 ) at week 2, and then remained unchanged through the treatment but decreased 4 weeks postwithdrawal (week 12). Levels of neutralizing antibodies in the Ad/LacZ group increased with repeated administration, but were much lower than in the treatment groups (p Ͻ 0.01), and then decreased at week 12. This latter result differs from that in the three treatment groups, in which levels remained relatively high at week 12 (Fig. 4C) .
To examine the effect of antibodies present in serum, a neutralization test based on a rapid assay for expression of green fluorescent protein (GFP) was developed. An E1-deleted replication-defective recombinant adenovirus expressing GFP was used to infect Vero cells; virus neutralization was assessed by evaluating GFP fluorescence 30 hr after infection. The neutralizing assay showed that 10 l of a serum sample mixture from the high-dose group collected at week 4 could completely neutralize 10 5 IFU of Ad/GFP (see Supplementary Fig. 1 at www.liebertonline.com/hum).
Antibodies against human IFN-␥
Antibodies against human IFN-␥ were assayed in serum acquired from monkeys at treatment weeks 0, 2, 4, 8, and 12. For the three groups receiving Ad/hIFN-␥, antibody levels increased at week 2 and reached maximal levels at week 4. These antibody levels remained up to 4 weeks after treatment ceased. The increase in antibodies was not dose dependent. The antibody was absent in the serum of the vector (Ad/LacZ) and excipient control groups (Fig. 4D) .
Discussion
IFN-␥ is an important cytokine in promoting both protective immune responses and immunopathologic processes in humans (Farrar and Schreiber, 1993; Bach et al., 1997; Boehm et al., 1997) . Extensive research has demonstrated that IFN-␥ also plays a vital role in antitumor responses (Ikeda et al., 2002; Khan et al., 2006) . In this study, the potential tox- icity of Ad/hIFN-␥ was evaluated in cynomolgus macaques before translating the delivery approach to the clinic. Cynomolgus macaques (Macaca fascicularis) are considered suitable animal models for the safety assessment of medicine because they share many common characteristics with humans. Study has shown that human IFN-␥ is active in nonhuman primate cells, and multidose studies in monkeys with recombinant human IFN-␥ were predictive of many of the dose-limiting clinical toxicities (Terrell and Green, 1993) . Ad/hIFN-␥ was given to male and female cynomolgus macaques in a treatment regimen that resembles a proposed clinical trial but at 2-200 times higher doses relative to body
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FIG. 2.
Representative histological sections of tissues from tested animals. Tissues (heart, liver, spleen, lung, kidney, brain, ovary, and testis) were fixed in 10% buffered formalin, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E).
weight. This relative overdose of the adenovirus given to animals ensured that any treatment-related side effects and toxicities would be intensified and therefore more likely to be detected. Injections were administered three times per week for eight successive weeks, and the recovery period was 1 month. Throughout the study, all animals appeared healthy, suggesting that injection of Ad/hIFN-␥ had no adverse effects on general health. Before treatment, during the 2 months of treatment, and during the recovery period, hematology, blood chemistry, urinalysis, ECG, and macroscopic and microscopic studies of test animals' organs and tissues revealed no significant abnormal toxic effects. The long-term toxicity study demonstrated that there was no significant toxicity associated with the intramuscularly delivered Ad/hIFN-␥, suggesting its potentially safe use in clinically therapeutic doses. Serum biochemical markers were measured at various times to assess tissue and liver damage. Different local routes of delivery of adenoviral vector have been reported to produce different hematology results: intratumoral and subcutaneous administration caused elevations in certain hematology and serum chemistry parameters (ALT and AST), whereas intradermal delivery did not (Sung et al., 2002; Wildner and Morris, 2002; Plog et al., 2006) . Our study showed that intramuscular administration of Ad/hIFN-␥ did not affect serum or urine chemistry profiles at 2-200 times the clinical dose.
Dose-dependent platelet reduction has been related to systemic administration of recombinant adenoviral vectors in some animal models and human clinical trials (O'Neal et al., 1998; Cichon et al., 1999; Morral et al., 2002; Raper et al., 2002) . In this study recombinant adenovirus was injected intramuscularly; no decrease in platelet counts was observed, nor was the prothrombin time (PT) affected. Similar to many previous findings in mice and rhesus monkeys (Schnell et al., 2001; Varnavski et al., 2002 Varnavski et al., , 2005 Mane et al., 2006) , intramuscularly administered recombinant adenovirus induced a transient decrease in WBC counts in the three Ad/hIFN-␥-treated groups in this study.
Real-time PCR provides a sensitive and quantitative assay for determining recombinant adenoviral vector dissemination. Recombinant adenoviral DNA could be detected in serum samples from the three treatment groups 4 hr after the initial intramuscular injection. The adenoviral copy number increased with time and peaked 24 hr postinjection. As expected, the serum of monkeys administered the high dose of Ad/hIFN-␥ had more recombinant adenoviral DNA than those treated with the low and mid-doses. Interestingly, different ratios of adenovirus leaked into the serum for each dose group. The ratio was about 5% for the low-dose group but was lower for the mid-and high-dose groups (2 and 1%, respectively). These results may be due to a possible higher clearance rate in the high-dose group because a strong immune reaction was induced.
Toxicity associated with in vivo administration of adenoviral vectors has been linked to activation of immune responses (Juillard et al., 1995; Muruve et al., 1997; Worgall et al., 1997) . The use of recombinant adenoviral vectors in many gene therapy trials suggests that the generation of humoral and cellular immune responses may limit the effect (Stallwood et al., 2000) . Neutralizing antibodies are a major part of the humoral immune response and are directed primarily against the adenoviral hexon protein (Vincent et al., 2001; Sumida et al., 2005) . Results showed that the human IFN-␥ transgene product markedly increased levels of neutralizing antibodies. We also determined the dominant isotypes of the anti-adenovirus antibodies at various time points. IgM was the dominant antibody at early stages, whereas IgG played a major role at, and after, week 4.
Abundant evidence states that, in some cases, transgene products can induce strong immune responses (Sun et al., 2003) . Anti-human IFN-␥ antibodies were detected in groups treated with Ad/hIFN-␥. Although the sequences of Macaca fascicularis IFN-␥ (GI: 1754524) and human IFN-␥ (GI: 47124535) are highly homologous (93%), they are still from different species; in addition, the nonhuman origin sequences of the adenoviral vector may induce a strong host immune reaction to the therapeutic gene. On the other hand, maintained expression of the transgene and repeated administration of the recombinant adenoviral vector can boost the immune system. We noticed that the same level of antihuman IFN-␥ antibodies was induced with different doses of Ad/hIFN-␥, possibly because multiple low doses are already sufficient to reach a threshold necessary for inducing antibodies to the therapeutic gene.
The results indicate that the antibody may prevent viral LI ET AL. 10   FIG. 3 . Recombinant viral genomes and IFN-␥ in serum after the first administration. They were measured using realtime PCR and ELISA kits, respectively. infection with repeated delivery and that it promotes the clearance of adenoviral vectors. The two factors, adenovirusneutralizing antibodies and anti-therapeutic gene antibodies, blocked the delivery of the transgene and therapeutic effects were compromised. Repeated administration of the adenoviral vector carrying the therapeutic gene or maintained expression of the transgene boosts the immune system, and finally limits the persistence of the therapeutic gene and efficacy of the therapy. In future, we will use the recombinant adenovirus Ad/hIFN-␥ for clinical use, so the anti-human IFN-␥ antibody may not be effective or it will be at a relatively low level. Thus, we have shown the profile of neutralizing antibodies against adenovirus and antibodies against the transgene product in monkey serum. These are important factors that should be taken into consideration in the design of gene therapy strategies. Monitoring antibody status will also become important in future clinical trials.
Overall, this preclinical toxicity study indicates that intramuscularly delivery of an adenovirus expressing human IFN-␥ is not toxic to cynomolgus macaques. The outcome of this study provides the safety support necessary to initiate clinical trials evaluating intratumor delivery of multiple doses of Ad/hIFN-␥ to treat substantial tumors. However, the production of neutralizing antibodies and possible immune responses against the transgene product may limit the therapeutic effect. The recombinant adenovirus Ad/hIFN-␥ is being considered for phase I clinical trials in cancer patients. Immune responses may be different in humans because cancer patients may have an abnormal or inhibited immune system after chemotherapy and/or radiotherapy. Furthermore, the high efficiency of adenoviral infection of host tumor cells, when it is administered to tumors, allows the adenovirus to avoid being neutralized by antibodies. Affinity columns consisting of recombinant capsid protein S could also be developed to remove neutralizing antibody from human serum to achieve better efficacy (Rahman et al., 2001 ). 
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